Standard BioTools

SomaLogic Merger And Illumina Partnership Will Unlock New Proteomics Opportunities

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

26 Mar 25

Updated

04 Dec 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-32.2%

7D

-0.7%

Loading

1Y

-32.2%

7D

-0.7%

You can edit this narrative until Dec 5 11:06 AM. Then, changes will post as Updates.

Author's Valuation

US$1.556.5% undervalued

AnalystConsensusTarget Fair Value

Shared on 04 Dec 25

LAB: Imaging Collaboration And Steady Outlook Will Support Future Earnings Profile

Analysts have modestly adjusted their price target on Standard BioTools, trimming fair value to approximately 1.55 dollars per share as they factor in a slightly higher discount rate, marginally softer long term profit margin expectations, and a higher projected future earnings multiple. What's in the News Molecular Instruments and Standard BioTools entered a strategic collaboration to develop next generation Imaging Mass Cytometry workflows powered by HCR imaging technologies, including the HCR HiFi Encoder for protein imaging with any primary antibody (Key Developments).

Shared on 20 Nov 25

Fair value Decreased 13%

LAB: Earnings Outlook Will Benefit From Advanced Imaging Collaboration

Analysts have adjusted their price target for Standard BioTools downward from $1.78 to $1.55. They cited updated expectations around revenue growth and profit margins.

Shared on 23 Aug 25

Fair value Decreased 6.58%

The downward revision in Standard BioTools' analyst price target reflects declining net profit margin and a higher future P/E ratio, with the consensus fair value now lowered to $1.78. What's in the News Standard BioTools announced a delay in filing their next 10-Q with the SEC.

Shared on 01 May 25

Fair value Decreased 17%

Shared on 24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Decreased 3.16%

AnalystConsensusTarget has decreased revenue growth from 7.3% to 6.0% and decreased shares outstanding growth rate from 0.0% to 0.0%.

AnalystConsensusTarget Fair Value

US$1.55

6.5% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

-20.65%

Life Sciences revenue growth rate

0.26%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.82%

Calculation

US$12.98m

Earnings '28

x

60.05x

PE Ratio '28

=

US$779.72m

Market Cap '28

US$779.72m

Market Cap '28

/

401.80m

No. shares '28

=

US$1.94

Share Price '28

US$1.94 Share Price '28

Discounted to 2025 @ 7.85% p.a.

=

US$1.55

Fair Value '25